In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure (Apr 2020)
CELLTOP Clinical Trial: First Report From a Phase 1 Trial of Autologous Adipose Tissue Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury (Feb 2020)
Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS (Nov 2016)
Adipose-derived mesenchymal stem cells from patients with atherosclerotic renovascular disease have increased DNA damage and reduced angiogenesis that can be modified by hypoxia (Sep 2016)